Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report

BACKGROUND: Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lishu, Liu, Lizhu, Han, Bo, Han, Wei, Zhao, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984462/
https://www.ncbi.nlm.nih.gov/pubmed/29855279
http://dx.doi.org/10.1186/s12885-018-4523-2
Descripción
Sumario:BACKGROUND: Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer. CASE PRESENTATION: Herein, we report a patient with advanced angiosarcoma, who received apatinib at a daily dose of 250 to 725 mg, resulting in a partial response for three months, which may be related to Kinase Insert Domain Receptor (KDR) gene amplification. CONCLUSION: Our experience reported here indicated that apatinib may be a useful therapeutic option for treatment of patients with advanced angiosarcoma.

Ejemplares similares